# Compass Therapeutics, Inc. (CMPX)

> Source: Nexqual · https://nexqual.com/CMPX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Compass Therapeutics, Inc. (CMPX), nexqual.com/CMPX" · informational, not investment advice.

**Price:** USD 0.9 (+2.01% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.88 · day 0.85–0.9 · 52w 0.82–6.88 · market cap $161M · NCM

## Key facts
- Analysts: Buy (mean 2.07 on a 1–5 scale) (15 analysts), mean target USD 5.45 (range 1–12).
- Total return with dividends: 1Y -80.2% vs S&P 500 +18.1%; 5Y -72.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.13, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $850K | $0K | — |
| Operating income | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M | -$81.1M |
| Net income | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M | -$73.4M |
| EPS (diluted) | -$1.31 | — | — | — | — | — |
| Free cash flow | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M | -$56.4M |
| Operating margin | — | — | — | -6661.8% | — | — |
| Net margin | — | — | — | -5808.8% | — | — |
| Revenue growth | — | — | — | — | -100.0% | — |
| Cash + short-term investments | $145M | $187M | $152M | $127M | $209M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 1.0x · FCF yield -34.91% · Earnings yield -45.48%

## Analysts
Consensus Buy (mean 2.07 on a 1–5 scale), 15 analysts; mean target USD 5.45 (low 1, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Craig-Hallum | Target lowered | Buy | $15 → $8 |
| 2026-09-23 | Citizens | Target lowered | Market Outperform | $10 → $4 |
| 2026-09-23 | Guggenheim | Target lowered | Buy | $8 → $4 |
| 2026-09-23 | Wedbush | Downgrade | Outperform → Neutral | $5 → $1 |
| 2026-09-23 | HC Wainwright & Co. | Target lowered | Buy | $24 → $12 |
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $4 → $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -80.2% | -72.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -80.3% | -22.5% |
| Volatility (annualized) | 127.4% | 91.2% |
| Max drawdown | -87.2% (Feb 2026→Oct 2026) | -86.9% (Feb 2026→Sep 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/CMPX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt